145 related articles for article (PubMed ID: 37797798)
1. Serum matrix metalloproteinase-9 (MMP9) and amyloid-beta protein precursor (APP) as potential biomarkers in children with Fragile-X syndrome: A cross sectional study.
Bekheet MHY; Mansour LA; Elkaffas RH; Kamel MA; Elmonem MA
Clin Biochem; 2023 Nov; 121-122():110659. PubMed ID: 37797798
[TBL] [Abstract][Full Text] [Related]
2. Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1KO mice.
Westmark CJ; Westmark PR; O'Riordan KJ; Ray BC; Hervey CM; Salamat MS; Abozeid SH; Stein KM; Stodola LA; Tranfaglia M; Burger C; Berry-Kravis EM; Malter JS
PLoS One; 2011; 6(10):e26549. PubMed ID: 22046307
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinase-9 deletion rescues auditory evoked potential habituation deficit in a mouse model of Fragile X Syndrome.
Lovelace JW; Wen TH; Reinhard S; Hsu MS; Sidhu H; Ethell IM; Binder DK; Razak KA
Neurobiol Dis; 2016 May; 89():126-35. PubMed ID: 26850918
[TBL] [Abstract][Full Text] [Related]
4. Incomplete silencing of full mutation alleles in males with fragile X syndrome is associated with autistic features.
Baker EK; Arpone M; Aliaga SM; Bretherton L; Kraan CM; Bui M; Slater HR; Ling L; Francis D; Hunter MF; Elliott J; Rogers C; Field M; Cohen J; Cornish K; Santa Maria L; Faundes V; Curotto B; Morales P; Trigo C; Salas I; Alliende AM; Amor DJ; Godler DE
Mol Autism; 2019; 10():21. PubMed ID: 31073396
[TBL] [Abstract][Full Text] [Related]
5. The feasibility and utility of hair follicle sampling to measure FMRP and FMR1 mRNA in children with or without fragile X syndrome: a pilot study.
Jalnapurkar I; Frazier JA; Roth M; Cochran DM; Foley A; Merk T; Venuti L; Ronco L; Raines S; Cadavid D
J Neurodev Disord; 2022 Dec; 14(1):57. PubMed ID: 36494616
[TBL] [Abstract][Full Text] [Related]
6. Novel roles of amyloid-beta precursor protein metabolites in fragile X syndrome and autism.
Westmark CJ; Sokol DK; Maloney B; Lahiri DK
Mol Psychiatry; 2016 Oct; 21(10):1333-41. PubMed ID: 27573877
[TBL] [Abstract][Full Text] [Related]
7. Fragile X and APP: a Decade in Review, a Vision for the Future.
Westmark CJ
Mol Neurobiol; 2019 Jun; 56(6):3904-3921. PubMed ID: 30225775
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of molecular approach in screening for fragile X premutation cases.
Refeat MM; El Saied MM; Abdel Raouf ER
Ir J Med Sci; 2023 Oct; 192(5):2265-2272. PubMed ID: 36409419
[TBL] [Abstract][Full Text] [Related]
9. [Fragile X syndrome and FMR1-dependent diseases - clinical presentation, epidemiology and molecular background].
Landowska A; Rzońca S; Bal J; Gos M
Dev Period Med; 2018; 22(1):14-21. PubMed ID: 29641417
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome.
Sheridan SD; Theriault KM; Reis SA; Zhou F; Madison JM; Daheron L; Loring JF; Haggarty SJ
PLoS One; 2011; 6(10):e26203. PubMed ID: 22022567
[TBL] [Abstract][Full Text] [Related]
11. Autism, Alzheimer disease, and fragile X: APP, FMRP, and mGluR5 are molecular links.
Sokol DK; Maloney B; Long JM; Ray B; Lahiri DK
Neurology; 2011 Apr; 76(15):1344-52. PubMed ID: 21482951
[TBL] [Abstract][Full Text] [Related]
12. Intercorrelation of Molecular Biomarkers and Clinical Phenotype Measures in Fragile X Syndrome.
Aishworiya R; Chi MH; Zafarullah M; Mendoza G; Ponzini MD; Kim K; Biag HMB; Thurman AJ; Abbeduto L; Hessl D; Randol JL; Bolduc FV; Jacquemont S; Lippé S; Hagerman P; Hagerman R; Schneider A; Tassone F
Cells; 2023 Jul; 12(14):. PubMed ID: 37508583
[TBL] [Abstract][Full Text] [Related]
13. Genetic reduction of MMP-9 in the Fmr1 KO mouse partially rescues prepulse inhibition of acoustic startle response.
Kokash J; Alderson EM; Reinhard SM; Crawford CA; Binder DK; Ethell IM; Razak KA
Brain Res; 2019 Sep; 1719():24-29. PubMed ID: 31128097
[TBL] [Abstract][Full Text] [Related]
14. Selective Deletion of Astroglial FMRP Dysregulates Glutamate Transporter GLT1 and Contributes to Fragile X Syndrome Phenotypes In Vivo.
Higashimori H; Schin CS; Chiang MS; Morel L; Shoneye TA; Nelson DL; Yang Y
J Neurosci; 2016 Jul; 36(27):7079-94. PubMed ID: 27383586
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic variability to medication management: an update on fragile X syndrome.
Elhawary NA; AlJahdali IA; Abumansour IS; Azher ZA; Falemban AH; Madani WM; Alosaimi W; Alghamdi G; Sindi IA
Hum Genomics; 2023 Jul; 17(1):60. PubMed ID: 37420260
[TBL] [Abstract][Full Text] [Related]
16. Unstable mutations in the FMR1 gene and the phenotypes.
Loesch D; Hagerman R
Adv Exp Med Biol; 2012; 769():78-114. PubMed ID: 23560306
[TBL] [Abstract][Full Text] [Related]
17. Finding novel distinctions between the sAPPα-mediated anabolic biochemical pathways in Autism Spectrum Disorder and Fragile X Syndrome plasma and brain tissue.
Ray B; Sokol DK; Maloney B; Lahiri DK
Sci Rep; 2016 May; 6():26052. PubMed ID: 27212113
[TBL] [Abstract][Full Text] [Related]
18. Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome.
Hoeffer CA; Sanchez E; Hagerman RJ; Mu Y; Nguyen DV; Wong H; Whelan AM; Zukin RS; Klann E; Tassone F
Genes Brain Behav; 2012 Apr; 11(3):332-41. PubMed ID: 22268788
[TBL] [Abstract][Full Text] [Related]
19. ICAM5 as a Novel Target for Treating Cognitive Impairment in Fragile X Syndrome.
Pei YP; Wang YY; Liu D; Lei HY; Yang ZH; Zhang ZW; Han M; Cheng K; Chen YS; Li JQ; Cheng GR; Xu L; Wu QM; McClintock SM; Yang Y; Zhang Y; Zeng Y
J Neurosci; 2020 Feb; 40(6):1355-1365. PubMed ID: 31882402
[TBL] [Abstract][Full Text] [Related]
20. Methylation of novel markers of fragile X alleles is inversely correlated with FMRP expression and FMR1 activation ratio.
Godler DE; Tassone F; Loesch DZ; Taylor AK; Gehling F; Hagerman RJ; Burgess T; Ganesamoorthy D; Hennerich D; Gordon L; Evans A; Choo KH; Slater HR
Hum Mol Genet; 2010 Apr; 19(8):1618-32. PubMed ID: 20118148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
